Form 4: RA Capital Management SEC Form 4 Filing for Vor Biopharma

RA Capital Management reports the acquisition of stock options by Dr. Andrew Levin on behalf of the investment fund.

Summary

• RA Capital Management, L.P. and associated entities reported the acquisition of 57,162 stock options in Vor Biopharma Inc. (VOR).
• The options have an exercise price of $14.09 per share.
• The options were granted on June 11, 2026, and expire on June 10, 2036.
• The options vest in 36 equal monthly installments starting July 11, 2026, contingent on Dr. Andrew Levin's continued service.
• The reporting persons disclaim beneficial ownership of the securities, noting they are held for the benefit of the RA Capital Healthcare Fund.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard compensation and governance procedures rather than a change in market sentiment or company outlook.

Positives

• Alignment of interests between a major institutional investor (RA Capital) and the issuer through board representation.
• Incentivization of key personnel (Dr. Andrew Levin) through long-term equity-based compensation.

Negatives

• The transaction involves the issuance of options, which may lead to future dilution of existing shareholders upon exercise.

Risks

• Vesting is subject to the continued service of Dr. Andrew Levin, creating key-person dependency.
• Market volatility could impact the value of the options relative to the $14.09 exercise price.

Future Outlook

The options vest over a 36-month period, indicating a long-term commitment to the issuer's performance and governance.

Management Comments

• The reporting persons disclaim beneficial ownership of the option and underlying common stock, except to the extent of their respective pecuniary interest.
• Dr. Levin is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser.

Industry Context

StockSavvy.ai notes that this filing reflects standard institutional governance practices in the biotech sector, where investment firms often hold board seats and receive equity compensation that is funneled back into the investment fund to offset management fees.

Comparison to Industry Standards

• The structure of the option grant is consistent with standard executive and director compensation packages in the biotechnology industry.
• The disclaimer of beneficial ownership is a common practice for institutional investors managing multiple funds.

Corporate Governance

Related Party Transactions

• Dr. Andrew Levin serves on the board of the issuer while being a Partner and Managing Director of the Adviser (RA Capital Management).

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of options beginning July 11, 2026.
• Continued monitoring of Dr. Andrew Levin's service to the board.

Key Dates

Keywords

Vor Biopharma, VOR, RA Capital Management, Form 4, Insider Trading, Stock Options, Biotech